A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER) Interim analysis


Daniel M. Geynisman, Philip Abbosh, Eric A. Ross, Matthew R. Zibelman, Pooja Ghatalia, Fern Anari, Katherine Ansel, James Ryan Mark, Lambros Stamatakis, Jean H. Hoffman-Censits, Rosalia Viterbo, Eric M. Horwitz, Mark A Hallman, R. Katherine Alpaugh, Richard E. Greenberg, Marc C. Smaldone, Robert Guy Uzzo, David Chen, Alexander Kutikov, Elizabeth R. Plimack

  • Follow up continues for the primary endpoint of 2 year MFS in ITT: 81.7% are so far w/o M1 dz
  • 77% of patients on active surveillance are alive, without M1 dz and with their bladder intact
  • 65% of patients on active surveillance have had some form of recurrence: 9/17 being NMIBC with bladder still intact
  • 11.5% of patients on active surveillance have had M1 dz vs. 23.6% in those w/o mut
  • HCRN GU16 257 and A031701 are ongoing
  • Risk adapted bladder preservation is NOT a standard of care

Download Publication